PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Afef Khanfir

Hopital Universitaire Habib Bourguiba

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs1 Trials Reviews1 Guidelines

Latest

Everything in the corpus, newest first.

AUG 13, 2026 · REVIEW

Efficacy and safety of adjuvant CDK4/6 inhibitors in hormone receptor–positive, HER2-negative early breast cancer: Updated evidence from a systematic review and meta-analysis

Journal of Oncology Pharmacy Practice

A rigorous meta-analysis of four Phase III RCTs with mature survival data demonstrating clear efficacy separation between drug classes (abemaciclib/ribociclib benefit vs palbociclib non-benefit) in a large population, with adequate power and low heterogeneity.

Strong EvidenceWala Ben Kridis Afef Khanfir Breast Cancer Treatment Studies

Reported

Sample size17784

Pooled HR (abemaciclib/ribociclib…0.69

95% CI for IDFS HR0.63–0.76

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support